ClinicalTrials.gg
RecruitingNCT06898853Updated May 5, 2026

The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes

An interventional study of 0.1% Ciclosporin A eye drops and Mineral oils eye drops in Dry Eye Disease (DED), sponsored by The University of New South Wales. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by The University of New South Wales · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Planned enrollment
17th of 41
60 · median 51
Started
2025
with 1 other
No phase
8 of 45
2 open now
Registered
39th of 45
by date

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 17th largest by planned enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 with no phase, and was the 39th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

Dry eye disease (DED) is a common, long-lasting condition that affects the surface of the eye. It happens when there's a problem with tear production or quality, which can lead to inflammation and discomfort. The immune system plays a big role in how DED develops and continues.

Researchers have found that in people with DED, there are more immune cells and inflammatory substances in the tears and on the eye's surface. This includes various types of immune cells, like T cells and dendritic cells, which are part of the body's defense system.

The first treatment for DED is usually artificial tears, but because the condition is chronic and can flare up, clinicians often use anti-inflammatory treatments too. One such treatment is cyclosporine A (CsA), which comes as eye drops. CsA works by reducing inflammation and affects how immune cells behave.

Researchers can study the immune cells on the eye's surface using a special microscopy technique called in vivo confocal microscopy (IVCM). A newer version of this method, called functional IVCM (Fun-IVCM), allows researchers to watch how these cells move and behave over time.

In the current study, researchers want to compare 0.1% CsA with a lubricating eye drop to see how they affect the immune cells on the eye's surface. The researchers will use Fun-IVCM to look at the number, shape, and movement of immune cells of the eye. The researchers will also collect samples from the eye's surface and tears to measure various markers of inflammation.

The goal is to better understand how CsA works in treating DED by directly observing its effects on the immune response in the eye, which is unexplored. This could help improve treatments for people suffering from this condition and expand the use of CsA in DED.

Read the detailed description

The immune system plays a pivotal role in dry eye disease (DED) pathogenesis. An increased level of several tear cytokines, chemokines, expression of HLA-DR molecules and activation of antigen presenting cells - dendritic cells (DCs), and lymphocytes all plays a central role in DED pathogenesis . The increased expressions of CD4+ and CD8+ T cells in the ocular surface of DED patients suggest a potential role of adaptive immunity in DED chronicity. The presence of antigen-presenting cells in the ocular surface and the upregulation of MHC II, IL-2, IL-17, IL-6 and IFN- γ and other co-stimulatory molecules in the tears of DED patients indicates a possible activation of the local adaptive immune response.

The conjunctiva serves as a primary site for immunological and histochemical analysis in ocular surface diseases . Researchers have employed various techniques to study ocular surface immunology such as impression cytology, conjunctival biopsy and through real-time polymerase chain reaction, immunocytochemistry, and light microscopy. Flow cytometry is a powerful technique that allows for the phenotypic analysis of cells through immunolabeling of extracellular expressions of various immune cell markers. An increased expressions of activation markers like HLA-DR and various immune cell populations including T cells (CD3+, CD4+, and CD8+), B cells, natural killer cells, and monocytes (CD14+ cells) are observed in DED using flow cytometry on conjunctival impression cytology samples .

Historically, studying human ocular surface immune cells required invasive techniques. With the advent of in vivo confocal microscopy (IVCM), has enabled real-time, non-invasive visualization of ocular surface epithelial immune cells (EICs) and corneal nerves. Over the past 20 years, researchers have used IVCM to examine pathologic changes in various ocular surface disorders. It is evident from several IVCM studies that corneal EICs undergoes changes such as increase in density and changes in its morphology in all forms of DED. Conventional static IVCM captures section images at a single time point of the corneal EIC's, and their analysis is limited to its density and morphology. While the in vivo nature of IVCM prevents direct immune cell phenotyping, the observed cells are predominantly believed to be DCs based on their morphological characteristics. Therefore, the authors have used the term EICs to define immune cells density (EIC density) quantified using static-IVCM. Unlike this method, which limits identification of the immune cell type, a recently pioneered, novel technique called functional IVCM (Fun-IVCM) enables identification of the immune cell types in the cornea by observing their morphodynamics. This method involves capturing consecutive sequence and volume scan images over a 30-40-minute period, with intervals of 4-5 minutes. The images are then time-lapsed to identify dynamic behaviour of each immune cell. Based on their dynamic behaviour and morphology, cells can be differentiated into either epithelial T cells (highly motile, smaller body size) or dendritic cells (DC's, less motile, larger body size with dendrites). Anterior corneal stromal macrophages can also be identified. Time-lapsed images allow for the examination of additional cell motility parameters, such as instantaneous speed and displacement speed.

The first-line treatment for DED is artificial tears. But, due to the chronic nature of the disease and recurrent acute exacerbations anti-inflammatory therapies has been largely implemented. Consequently, many of the current therapeutic approaches target various inflammatory pathways, aiming to break the vicious cycle of DED. Both topical corticosteroids and immunosuppressants effectively reduce inflammation in DED. Topical corticosteroids are used in DED to control acute exacerbations of inflammation of the ocular surface, but their longer-term use is limited by their iatrogenic ocular side-effects. To contrast this, immunosuppressive agents such as ciclosporin A (CsA) have potential anti-inflammatory effect, with minimal local side-effects. The use of CsA in chronic DED can significantly reduce ocular surface staining, redness, inflammatory markers and improves dry eye symptoms. In brief, CsA dampens T cell proliferation by inhibiting the phosphatase calcineurin. CsA functions at different steps of the immune response, during antigen presentation and DC-T cell interaction. Innate immune cells are now seen as potentially important targets of CsA and may reflect simultaneous targeting of dendritic cells, macrophages, and neutrophils. In the ocular surface preliminary evidence suggest that CsA can significantly reduce activation markers such as HLA-DR, CD11c, certain apoptosis markers, and conjunctival T lymphocytes accompanied the clinical improvement in CsA-treated DED patients.

While a handful of clinical trials have evidenced the efficacy of CsA in reducing inflammation and improving symptoms of DED, the direct effect of CsA on ocular surface immune cells has not been studied in detail using static and using Fun-IVCM. Given the effect of CsA on both innate and adaptive immune cells, the authors hypothesise that the use of 0.1% CsA will have an inhibitory effect on the ocular surface immune response along with improvement of signs and symptoms of DED compared with its vehicle. This paper highlights the randomized clinical trial protocol to comprehensively study the effect of CsA on the ocular surface innate and adaptive immune system in DED. The study will investigate CsA's impact on DCs (CD11c+ DCs, HLA-DR), T helper cell populations (CD4+ T cells) through analysis of lymphocyte markers (CD45, CD3, CD4) and their associated cytokines (Th1 pathway cytokines), particularly IL-2, IFN- γ and IL-17 which is a primary target of CsA's immunomodulatory action.

1.2. Study aims and hypothesis Aim 1: To investigate and compare the effect of 12-weeks topical 0.1% CsA therapy on ocular surface innate and adaptive immune cells using imaging - Static-IVCM and Fun-IVCM (immune cell density, morphology and morphodynamic behaviours), immune cell phenotyping using conjunctival impression cytology and flow cytometry techniques and tear cytokine analysis (Multiplex bead assay assessing tear concentrations of IL-2, IL-4, IL-6, IL-12, IL-17, IL-23, IFN- γ) Hypothesis: CsA will have an inhibitory effect on the ocular surface innate and adaptive immune cell density, morphology and tear cytokines in DED.

Aim 2: To assess the association between DED signs, symptoms and immune cell characteristics and tear cytokines in DED Hypothesis: A direct relationship between immune cell characteristics, teat cytokines and DED signs, symptoms exist.

Aim 3: To investigate the temporal relationship between immune cell changes and clinical improvement Hypothesis: Changes in immune cell characteristics (density and dynamics) and inflammatory markers precede clinical improvement in signs and symptoms of DED following CsA treatment.

03

Conditions studied

  • Dry Eye Disease (DED)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age and above
  2. Participants should meet any two of the following DED diagnostic criteria: i) ocular surface disease index score of ≥23 and ii) Oxford staining score of ≥1 iii) Tear meniscus height \< 0.2 mm.

Exclusion criteria

Exclusion Criteria:

  1. Participants currently using or with previous use of , ciclosporin, lifitegrast or any anti-inflammatory eye drops in the last 6 months.
  2. Participants with systemic CsA or tacrolimus
  3. Known or to the study medication or any of its ingredients.
  4. Active intraocular inflammation.
  5. Contact lens wear or the use of contact lenses in the last 4 weeks.
  6. Active eye infections or history of critical illness.
  7. DED secondary to Steven-Johnson syndrome and cicatricial conjunctival disease.
  8. Participants with other ocular co-morbidities and medications for glaucoma.
  9. Participants with previous history of ocular surgery in the past 6 months.
  10. Any other active or inactive systemic condition, structural abnormality such as eyelid malposition's that in the judgment of the investigator could confound study assessments or limit compliance.
  11. Pregnant/breastfeeding women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A - CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) once daily at night-time + Cationorm

    Drug: 0.1% Ciclosporin A eye drops · Drug: Mineral oils eye drops

  • Active comparator
    Group B - Cationorm (CSL Seqirus, Parkville, Victoria) four times daily in both eyes for 12-weeks.

    Drug: Mineral oils eye drops

Interventions

  • DrugCyclosporineStudies of CyclosporineCyclosporine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The active intervention arm has CsA 0.1% - Ikervis (CSL Seqirus, Parkville, Victoria) and mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)

  • DrugMineral oils eye drops

    This arm is the comparator arm has mineral oils lubricating eye drops - Cationorm (CSL Seqirus, Parkville, Victoria)

06

What researchers measure

Primary outcomes

  1. Corneal epithelial immune cell density

    Evaluation of change in corneal epithelial immune cell density using in vivo confocal microscopy. The outcome will be measured as the number of immune cells per square millimeter (cells/mm²) of corneal epithelium. Higher values indicate increased immune cell infiltration and greater corneal inflammation.

    Time frame: Baseline, 4-weeks, and 12-weeks

  2. Conjunctival immune cell density

    Evaluation of change in conjunctival immune cell density using impression cytology and flow cytometry. The outcome will be measured as the percentage change in specific immune cell populations (including CD45, CD3, CD4, CD8, CD11c, and HLA-DR positive cells). Higher percentage indicates an increase in immune cell density.

    Time frame: Baseline, 4-weeks and 12-weeks.

Secondary outcomes

  1. Tear cytokine concentrations

    Evaluation of change in tear film inflammation through measurement of cytokine concentrations in tear fluid. The concentration of each inflammatory cytokine (IL-2, IL-4, IL-6, IL-12, IL-17, IL-23, IFN-γ) will be individually measured and reported in picograms per milliliter (pg/mL). Higher concentrations indicate more severe ocular surface inflammation.

    Time frame: Baseline and 12-weeks.

  2. Tear film break-up time

    Evaluation of change in tear-film break-up time observed through slit-lamp biomicroscopy after fluorescein dye instillation in the eye. The measurement is recorded in seconds, with lower values indicating decreased tear film stability and more severe dry eye disease. A value of \<10 seconds is considered abnormal

    Time frame: Baseline, 4-weeks, and 12-weeks.

  3. Ocular surface disease index score

    Evaluation of change in dry eye symptoms using the Ocular Surface Disease Index (OSDI) questionnaire. The OSDI is a validated 12-item questionnaire that assesses symptoms related to dry eye disease and their impact on vision-related functioning. The scale ranges from 0 to 100 points, with higher scores indicating more severe dry eye symptoms

    Time frame: Baseline, 4-weeks and 12-weeks.

  4. Ocular surface staining score

    Evaluation of change in ocular surface staining score using the Oxford Staining grading. The Oxford Staining Score is a standardized grading system that quantifies corneal and conjunctival epithelial damage by assessing the degree of fluorescein and/or lissamine green staining. The scale ranges from 0 to 5 points (or grades), with higher scores indicating more severe ocular surface damage.

    Time frame: Baseline, 4-weeks and 12-weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 200 non-industry interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 25. This study's planned 18 months is above that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2025
First posted
Mar 27, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06898853
Lead sponsor
The University of New South Wales
Collaborators
University of Melbourne
Responsible party
Soumen Sadhu (Coordinating Investigator, The University of New South Wales) — Principal investigator
First posted
Mar 27, 2025
Start date
Jun 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Fiona Stapleton Professor, PhD
Contact
f.stapleton@unsw.edu.au
+61 0418868234
Fiona Stapleton Professor, PhD
principal investigator · The University of New South Wales

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion